Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403894 | 0.70 | MTOR (0.43) | NISCH | |
| SCHEMBL2652004 | 0.69 | AMY1A (0.35) | — | |
| SCHEMBL1119442 | 0.67 | GFER (0.46) | NOTUMNISCH | |
| SCHEMBL6002502 | 0.67 | AHR (0.46) | NOTUM | |
| SCHEMBL28536153 | 0.67 | APP (0.46) | — | |
| SCHEMBL28536156 | 0.67 | NISCH (0.47) | NISCH | |
| SCHEMBL4049587 | 0.67 | ALDH1A1 (0.41) | — | |
| SCHEMBL4052094 | 0.67 | NOTUM (0.38) | NOTUMNISCH | |
| SCHEMBL4015570 | 0.66 | SCN2A (0.55) | NOTUM | |
| SCHEMBL2091213 | 0.66 | IDO1 (0.45) | NOTUMNISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589096-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1566384-B1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-20080188507-A1 | Novel azole derivatives | MSD K.K. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7365079-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| EP-1534074-A4 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1799241-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060111380-A1 | Novel azole derivatives | MSD K.K. (JP) | 2006-05-25 | — | — | US | disclosed |
| WO-2006036770-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| EP-1635832-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1635813-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | Merck & Co. Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1635773-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1566384-A1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-24 | — | — | EP | disclosed |
| EP-1534074-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005000217-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004110375-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110368-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004009015-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188507-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | NOTUM 2706/4885NISCH 1902/4885 |
| US-20060111380-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | NOTUM 2436/4885NISCH 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.